INSULET CORP PODD

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

Insulet Corporation ("we" or the "Company") is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod® 5 Automated Insulin Delivery System ("Omnipod 5"), the Omnipod DASH® Insulin Management System ("Omnipod DASH"), and the Omnipod Insulin Management System ("Classic Omnipod").

We also produce pods for Amgen for use in the Neulasta® Onpro® kit, a delivery system for Amgen's Neulasta to help reduce the risk of infection after intense chemotherapy.

Diabetes is a chronic, life-threatening disease for which there is no known cure. It is caused by the body's inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels. Glucose, the primary source of energy for cells, must be maintained at certain concentrations in the blood in order to permit optimal cell function and health. In people with diabetes, blood glucose levels fluctuate between very high levels, a condition known as hyperglycemia, and very low levels, a condition called hypoglycemia. Hyperglycemia can lead to serious short-term complications, such as confusion, vomiting, dehydration, and loss of consciousness and long-term complications, such as blindness, kidney disease, nervous system disease, occlusive vascular diseases, stroke, cardiovascular disease, or death. Hypoglycemia can lead to confusion, loss of consciousness, or death.

Last close 149.01 2026-10-23
Market cap $10.33B 2026-06-30 share count
52-week range 126.40 - 354.88

Valuation FY2025 figures against the last close

P/S3.8x
P/E42.8x
P/FCF27.4x
EV/EBITDA17.1x
Dividend yield—
Diluted EPS3.48

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • U.S.
  • International
Revenue by geography, 2 categories over 3 years. The same figures are in the table below. FY2025 U.S., FY2025: 2B (72.1%) 72% U.S. International, FY2025: 754.3M (27.9%) 28% International FY2024 U.S., FY2024: 1.5B (74.7%) 75% International, FY2024: 523.4M (25.3%) 25% FY2023 U.S., FY2023: 1.3B (75.8%) 76% International, FY2023: 410.1M (24.2%) 24%
Region FY2025FY2024FY2023
U.S. $1.95B $1.55B $1.29B
International $754.3M $523.4M $410.1M

As the company reported it, from the “Segment and Geographic Data - Revenue by Geographic Location (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $2.71B$2.07B$1.70B$1.31B$1.10B$904.4M$738.2M$563.8M$463.8M$367.0M
Cost of revenue $768.2M$625.9M$537.2M$499.7M$346.7M$322.1M$257.9M$193.6M$186.6M$155.9M
Gross profit $1.94B$1.45B$1.16B$805.6M$752.1M$582.3M$480.3M$370.2M$277.2M$211.1M
R&D $301.1M$219.6M$205.0M$180.2M$160.1M$146.8M$132.3M$94.8M$75.7M$55.7M
SG&A $1.17B$917.2M$734.8M$587.8M$466.0M$384.0M$298.0M$248.0M$84.7M$71.6M
Total operating expenses ——————$430.3M$342.8M$284.6M$221.8M
Operating income $473.8M$308.9M$220.1M$37.6M$126.0M$51.5M$50.0M$27.4M-$7.4M-$10.7M
Interest expense $59.4M$42.7M$36.2M$36.0M$61.7M$48.1M$34.6M$28.9M$21.2M$14.4M
Pre-tax income $339.5M$300.2M$214.7M$9.8M$20.5M$9.7M$14.5M$5.2M-$26.6M-$26.8M
Income tax $92.4M$118.1M$8.3M$5.2M$3.7M$2.9M$2.9M$1.9M$200.0K$392.0K
Net income $247.1M$418.3M$206.3M$4.6M$16.8M$6.8M$11.6M$3.3M-$26.8M-$28.9M
EPS, basic 3.515.972.960.070.250.110.190.06-0.46-0.48
EPS, diluted 3.485.782.940.070.240.100.190.05-0.46-0.48
Shares, diluted (wtd. avg.) 71.9M73.9M73.6M69.9M68.6M65.9M62.3M61.0M58.0M57.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $716.1M$953.4M$704.2M$689.8M$806.4M$922.0M$213.7M$113.9M$272.6M$137.2M
Short-term investments ————$0$40.4M$162.4M$175.0M——
Receivables ———$140.9M$135.2M$95.3M$69.3M$63.3M$53.4M$28.8M
Inventory $452.6M$430.4M$402.6M$346.8M$303.2M$154.3M$101.0M$71.4M$33.8M$35.5M
Total current assets $1.91B$1.89B$1.58B$1.31B$1.33B$1.25B$591.0M$461.3M$537.2M$370.0M
Property, plant and equipment ———$599.9M$536.5M$478.7M$399.4M$258.4M$107.9M$44.8M
Goodwill $51.6M$51.5M$51.7M$51.7M$39.8M$39.8M$39.8M$39.6M$39.8M$39.7M
Other intangibles $117.1M$98.5M$98.7M$75.5M$36.6M$28.7M$13.2M$10.4M$4.4M$2.0M
Total assets $3.19B$3.09B$2.59B$2.25B$2.05B$1.87B$1.14B$928.7M$816.7M$456.6M
Accounts payable $75.0M$19.8M$19.2M$30.8M$37.7M$54.1M$54.5M$25.5M$24.4M$13.2M
Short-term debt $18.4M$83.8M$49.4M$27.5M$25.1M$15.6M$0———
Total current liabilities $680.1M$528.4M$451.2M$364.7M$228.8M$207.8M$157.7M$115.7M$86.0M$55.7M
Long-term debt ———$1.37B$1.25B$1.04B$887.9M$592.0M$566.2M$332.8M
Total liabilities $1.68B$1.88B$1.86B$1.77B$1.49B$1.27B$1.07B$716.6M$658.2M$393.5M
Retained earnings $287.4M$40.3M-$378.0M-$584.3M-$649.5M-$666.3M-$672.0M-$683.6M-$707.3M-$680.4M
Total equity $1.52B$1.21B$732.7M$476.4M$556.3M$603.6M$75.9M$212.1M$158.5M$63.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $569.3M$430.2M$145.7M$119.0M-$68.1M$84.0M$98.4M$35.9M$41.3M$15.9M
Depreciation and amortisation $90.4M$80.8M$72.8M$63.2M$57.4M$55.4M$27.9M$15.6M$13.9M$13.8M
Stock-based compensation $62.7M$69.3M$48.4M$40.9M$34.4M$35.9M$28.7M$37.5M$31.9M$23.6M
Capital expenditure $191.6M$124.9M$75.6M$122.9M$111.9M$129.0M$163.7M$157.4M$73.8M$22.1M
Investing cash flow -$222.7M-$146.2M-$119.4M-$191.1M-$82.7M$14.0M-$73.6M-$184.5M-$210.8M-$178.0M
Financing cash flow -$595.3M-$28.0M-$13.6M-$40.3M$40.7M$605.5M$73.5M-$8.7M$304.5M$176.6M
Buybacks $59.6M$0$0———————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-013333.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B 0 1B 2B 3B Revenue, FY2016: 367M Gross profit, FY2016: 211.1M Net income, FY2016: -28.9M Revenue, FY2017: 463.8M Gross profit, FY2017: 277.2M Net income, FY2017: -26.8M Revenue, FY2018: 563.8M Gross profit, FY2018: 370.2M Net income, FY2018: 3.3M Revenue, FY2019: 738.2M Gross profit, FY2019: 480.3M Net income, FY2019: 11.6M Revenue, FY2020: 904.4M Gross profit, FY2020: 582.3M Net income, FY2020: 6.8M Revenue, FY2021: 1.1B Gross profit, FY2021: 752.1M Net income, FY2021: 16.8M Revenue, FY2022: 1.3B Gross profit, FY2022: 805.6M Net income, FY2022: 4.6M Revenue, FY2023: 1.7B Gross profit, FY2023: 1.2B Net income, FY2023: 206.3M Revenue, FY2024: 2.1B Gross profit, FY2024: 1.4B Net income, FY2024: 418.3M Revenue, FY2025: 2.7B Gross profit, FY2025: 1.9B Net income, FY2025: 247.1M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $367.0M $463.8M $563.8M $738.2M $904.4M $1.10B $1.31B $1.70B $2.07B $2.71B
Gross profit $211.1M $277.2M $370.2M $480.3M $582.3M $752.1M $805.6M $1.16B $1.45B $1.94B
Net income -$28.9M -$26.8M $3.3M $11.6M $6.8M $16.8M $4.6M $206.3M $418.3M $247.1M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Regulation FD disclosure Item 7.01
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%